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Summary. Background: D-dimer concentrations have not
been evaluated extensively as a predictor of increased
venous thromboembolism (VTE) risk in acutely ill, hospitalized medical patients. Objectives: To analyze the relationships between D-dimer concentration, VTE and
bleeding in the MAGELLAN trial (NCT00571649).
Patients/methods: This was a multicenter, randomized,
controlled trial. Patients aged ≥ 40 years, hospitalized for
acute medical illnesses with risk factors for VTE received
subcutaneous enoxaparin 40 mg once daily for
10  4 days then placebo up to day 35, or oral rivaroxaban 10 mg once daily for 35  4 days. Patients
(n = 7581) were grouped by baseline D dimer ≤ 2 9 or
> 2 9 the upper limit of normal. VTE and major plus
non-major clinically relevant bleeding were recorded at
day 10, day 35, and between days 11 and 35. Results: The
frequency of VTE was 3.5-fold greater in patients with
high D-dimer concentrations. Multivariate analysis
showed that D-dimer was an independent predictor of the
risk of VTE (odds ratio 2.29 [95% confidence interval
1.75–2.98]), and had a similar association to established
risk factors for VTE, for example cancer and advanced
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age. In the high D-dimer group, rivaroxaban was noninferior to enoxaparin at day 10 and, unlike the low Ddimer group, superior to placebo at day 35 (P < 0.001)
and days 11–35 (P < 0.001). In both groups, bleeding
outcomes favored enoxaparin/placebo. Conclusions: Elevated baseline D-dimer concentrations may identify
acutely ill, hospitalized medical patients at high risk of
VTE for whom extended anticoagulant prophylaxis may
provide greater benefit than for those with low D-dimer
concentrations.
Keywords: D-dimer;
enoxaparin;
rivaroxaban; venous thromboembolism.

hospitalization;

Introduction
Acutely ill, hospitalized medical patients, such as those
with active cancer or those who have experienced a
stroke, acute heart failure, infection, inflammation or
respiratory failure, are at substantial risk of venous
thromboembolism (VTE) [1]. Studies have shown that this
risk may continue beyond the standard duration of anticoagulant therapy [2–4], but determining the optimal
duration of thromboprophylaxis in this heterogeneous
patient population is challenging [3–5].
Three randomized clinical trials have investigated the
use of extended anticoagulant therapy in acutely ill, hospitalized medical patients. In the EXCLAIM study, after
an initial open-label 10  4 day course of enoxaparin, a
further 28  4 days of therapy significantly reduced the
overall incidence of VTE compared with placebo [4]. Subsequently, the MAGELLAN study investigated the effect
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on VTE incidence of extended prophylaxis (35  4 days)
using the oral, direct factor Xa inhibitor rivaroxaban
compared with standard-duration subcutaneous enoxaparin (10  4 days) followed by oral placebo [6]. In
MAGELLAN, rivaroxaban was shown to be non-inferior
compared with enoxaparin at day 10 in terms of VTE
incidence, and superior to enoxaparin followed by placebo at day 35 [3]. The ADOPT study investigated the
effect on VTE risk of thromboprophylaxis with apixaban
given for 30 days compared with enoxaparin given for
between 6 and 14 days, but failed to show superiority for
the extended apixaban regimen [5].
In all three studies, overall bleeding rates were low.
However, the extended prophylaxis regimens carried a
significantly increased risk of major bleeding in
EXCLAIM and ADOPT and of clinically relevant bleeding (major plus non-major clinically relevant bleeding) in
MAGELLAN vs. the comparator arms. Therefore, for all
three studies, the benefit–risk balance for extended thromboprophylaxis in the overall study populations was not
favorable [3–5].
A preliminary univariate analysis of the MAGELLAN
data identified baseline D-dimer concentration as an independent predictive factor for VTE (data on file).
D dimer is a fibrin degradation product that occurs as a
result of thrombus fibrinolysis [7], and elevated concentrations have previously been associated with an increased
risk of VTE in acutely ill patients [8,9]. Because D-dimer
is a sensitive (typically 85–95%, dependent on assay) but
non-specific (50–70%) marker of thrombosis that is
widely used in clinical practice as a diagnostic aid for suspected VTE [7,10], it was hypothesized that D-dimer concentrations could be employed to identify a subgroup of
acutely ill patients at high risk of VTE for whom the benefit–risk balance of extended thromboprophylaxis might
be favorable. In this subanalysis, the relationship between
D-dimer concentrations, thromboprophylaxis and efficacy
and safety outcomes in the MAGELLAN study were
evaluated.
Methods
Study design and endpoints

The MAGELLAN protocol and inclusion criteria have
been reported previously [6]. Briefly, patients aged
≥ 40 years who were hospitalized for various acute medical illnesses with risk factors for VTE, and who had an
anticipated survival of > 6 months, were randomized to
receive either subcutaneous enoxaparin 40 mg once daily
for 10  4 days followed by placebo up to day 35, or
oral rivaroxaban 10 mg once daily for 35  4 days.
The primary efficacy endpoints were the composite incidence of asymptomatic proximal deep vein thrombosis,
symptomatic deep vein thrombosis, symptomatic nonfatal pulmonary embolism and VTE-related death up to

day 10 and day 35. The principal safety outcome was the
composite of treatment-emergent major bleeding and
non-major clinically relevant bleeding at day 10 and day
35. Overt bleeding episodes falling outside these criteria,
on-treatment adverse events and laboratory parameters
were secondary safety outcomes [6].
As per protocol, D-dimer concentrations were determined at baseline (day 1; prior to receiving the first dose
of study medication and between 2 and 4 h afterwards)
and on day 10 pre- and post-dose. The pre-dose concentration was used unless missing, in which case the postdose value was used. All analyses were conducted at a
central laboratory using the STA Liatest D-DI (Diagnostica Stago, Asnieres-sur-Seine, France) assay, which has
an upper limit of normal (ULN) of 0.5 lg mL 1. This is
a quantitative assay of D-dimer antigen in citrated plasma
by the immunoturbidimetric method based on measurement of light absorbance produced by a suspension of microlatex particles coated with specific mouse anti-human
D-dimer monoclonal antibodies. The results of D-dimer
tests were not provided to treating physicians.
Subanalysis design and endpoints

In MAGELLAN, the overall median baseline D-dimer
concentration was 0.94 lg mL 1, which corresponds to
approximately twice the ULN. Therefore, patients were
grouped post-hoc according to whether their D-dimer concentration was ≤ 2 9 ULN or > 2 9 ULN, and a multivariate analysis was conducted using this cut-off. The
multivariable logistic regression model included treatment
group and D-dimer concentration at baseline, and applied
a stepwise variable selection (using an entry level of
P = 0.3, which was considered appropriate based on
exploratory analyses) for additional covariates including
sex, age ≥ 75 years, body mass index, creatinine clearance, geographic region, all acute medical conditions
present, baseline high-sensitivity C reactive protein, history of VTE, and recent major surgery. Receiver operating characteristic (ROC) analysis was performed for the
incidence of VTE at day 10 and day 35; the area under
the ROC curve for D-dimer at baseline and the positive
and negative predictive values, sensitivity and 1-specificity
were derived; ROC results were also derived for two
other VTE risk scores for hospitalized medical patients –
IMPROVE [11] and PRETEMED [12,13] – to evaluate
the predictive value of baseline D-dimer for VTE.
Venous thromboembolism and major and non-major
clinically relevant bleeding were analyzed for the group of
patients with a baseline D-dimer concentration
> 2 9 ULN (the high D-dimer group) and for those with
a baseline D-dimer concentration ≤ 2 9 ULN (the low
D dimer group). An exploratory analysis of the above
outcomes by D-dimer concentration occurring during the
extended prophylaxis period (days 11–35) was also
conducted. Criteria for inclusion in the populations evalu© 2014 International Society on Thrombosis and Haemostasis
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ated for efficacy and safety have been reported previously
[6]. The per-protocol population was the primary population used for analysis of non-inferiority at day 10,
whereas the modified intention-to-treat population was
the efficacy population for superiority analysis at day 35.
The safety population comprised all patients who received
a study drug. In the current analysis, the efficacy population was used for post-hoc evaluation of efficacy during
the extended prophylaxis period.
Statistical methods

In the analyses presented here, for VTE and bleeding
outcomes, relative risk (RR) ratios (rivaroxaban vs.
enoxaparin or rivaroxaban vs. enoxaparin/placebo) were
estimated based on asymptotic methods. If not noted
otherwise, two-sided P values and two-sided 95% confidence intervals (CIs) were calculated for tests.

Results
Baseline patient characteristics by D-dimer concentration

MAGELLAN randomized 8101 patients from 556 sites in
52 countries between December 2007 and July 2010 (Fig.
S1) [3]. Of these, 7581 patients had D-dimer measurements (of which the post-dose D-dimer value was used in
7.6% and 5.3% of patients valid for safety analysis at
baseline and day 10, respectively). Baseline characteristics
by D-dimer concentration are shown in Table 1. Compared with the low D-dimer group, patients in the high
D-dimer group were slightly older, had a lower body
mass index, and had a higher incidence of heart failure,
active cancer, infection or inflammation, and additional
risk factors for VTE, but a lower incidence of acute ischemic stroke and respiratory insufficiency.
Venous thromboembolism by D-dimer concentration

Study oversight, registration and role of the funding source

The MAGELLAN study was conducted in accordance
with the Declaration of Helsinki and local regulations.
The protocol was approved by the local Institutional
Review Board or Ethics Committee and written
informed consent was obtained from each patient prior
to any study-specific procedures. The study was supported by research funding from Bayer HealthCare
Pharmaceuticals and Janssen Research & Development,
LLC to the MAGELLAN study group, and was
designed and supervised by the MAGELLAN Steering
Committee. Data were collected and analyzed by the
study sponsors. All authors contributed to writing the
manuscript, had full access to the data and analyses,
and vouch for the accuracy and completeness of the
report. The Steering Committee made the decision to
publish. This trial was registered at www.clinicaltrials.
gov as NCT00571649.

D-dimer concentrations at baseline and day 10 for
patients with or without VTE at day 10 and day 35 are
shown in Table 2; patients with VTE had a mean baseline
D-dimer concentration that was higher than those who
did not. Patients with high D-dimer concentrations at
baseline and day 10 were more likely to have VTE by day 35
than those with lower concentrations, regardless of treatment (Fig. S2). Overall, 106 of 2662 (4.0%) patients in
the high D-dimer group had a venous thromboembolic
event by day 10, compared with 35 of 3037 (1.2%) in the
low D-dimer group. The absolute VTE rate increased
with rising baseline D-dimer concentration in both study
arms, and was more pronounced with enoxaparin than
rivaroxaban at day 10 (data not shown) and with enoxaparin/placebo at day 35 (Fig. 1).
The outcome of the multivariate analysis at day 35
confirmed that D-dimer concentration > 2 9 ULN compared with ≤ 2 9 ULN was an independent predictor of

Table 1 Patient characteristics at entry by baseline D-dimer concentration (safety population)
> 2 9 ULN (high D-dimer group)

≤ 2 9 ULN (low D-dimer group)

Parameter

Rivaroxaban
n = 1781

Enoxaparin/placebo
n = 1834

Rivaroxaban
n = 2003

Enoxaparin/placebo
n = 1963

Age, mean, years
Weight, mean, kg
Height, mean, cm
BMI, mean, kg m 2
Male,%
Heart failure, %
Active cancer, %
Acute ischemic stroke, %
Infection/inflammation, %
Respiratory insufficiency, %
Additional risk factor for VTE, %

71.4
75.2
165.0
27.5
53.1
34.5
9.0
11.5
52.4
25.7
45.3

71.3
75.8
165.0
27.7
49.6
36.4
8.5
11.5
51.5
27.5
44.1

67.3
79.1
166.0
28.7
58.4
30.7
6.0
22.8
42.8
27.7
40.6

67.2
78.8
165.0
28.7
55.7
29.8
6.0
22.9
42.0
29.9
41.5

Baseline D-dimer concentration

BMI, body mass index; ULN, upper limit of normal; VTE, venous thromboembolism.
© 2014 International Society on Thrombosis and Haemostasis
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Table 2 D-dimer concentrations at baseline and day 10 for patients with and without VTE at days 10 and 35
Rivaroxaban

Time point/outcome
Baseline D-dimer
Day 10 with VTE*
Day 10 without VTE*
Day 35 with VTE†
Day 35 without VTE†
Days 11–35 with VTE†
Days 11–35 without VTE†
Day 10 D-dimer
Day 35 with VTE†
Day 35 without VTE†
Days 11–35 with VTE†
Days 11–35 without VTE†

Enoxaparin/placebo

n

D-dimer concentration,
lg mL 1 mean (SD)

95% CI

n

D-dimer concentration,
lg mL 1 mean (SD)

95% CI

77
3707
122
3662
66
3718

2.14
1.35
2.07
1.34
1.84
1.36

(1.34)
(1.13)
(1.30)
(1.13)
(1.24)
(1.14)

1.84–2.45
1.31–1.39
1.83–2.30
1.31–1.38
1.53–2.14
1.32–1.40

77
3720
161
3636
106
3691

2.48
1.35
2.24
1.34
2.24
1.35

(1.39)
(1.13)
(1.28)
(1.13)
(1.25)
(1.14)

2.16–2.79
1.32–1.39
2.04–2.44
1.30–1.37
1.99–2.48
1.31–1.39

92
3221
52
3261

1.67
1.03
1.69
1.04

(1.25)
(1.01)
(1.30)
(1.01)

1.41–1.93
1.00–1.07
1.33–2.06
1.00–1.07

138
3233
98
3273

1.70
1.01
1.71
1.02

(1.15)
(0.96)
(1.10)
(0.97)

1.51–1.89
0.98–1.05
1.49–1.93
0.99–1.05

CI, confidence interval; SD, standard deviation; VTE, venous thromboembolism. *Per-protocol population. †Efficacy population.

11
10
9

Event rate (%)

8
7
6
5
4
3
Rivaroxaban

2

Enoxaparin/placebo

1
0
> 0.1

> 0.3

> 0.5

> 0.7

> 0.9

> 1.1

> 1.3

> 1.5

D-dimer concentration at baseline (µg mL–1)
Fig. 1. Absolute event rate for venous thromboembolism at day 35
by treatment arm and baseline D-dimer concentration. Results are
shown for the efficacy population.

the risk of VTE (odds ratio [OR], 2.29; 95% CI, 1.75–
2.98; Table 3). The area under the ROC curve for
D-dimer at baseline ranged between 0.67 and 0.74,
depending on the day of VTE assessment and treatment
group, with larger values for enoxaparin and placebo
than for rivaroxaban (Table S1 and Fig. S3). Baseline
D-dimer concentration had a similar predictive value for
VTE to the IMPROVE risk score at admission and during hospitalization, and the PRETEMED risk score,
when applied to the MAGELLAN data (Table S2).
Venous thromboembolism incidence by D-dimer group
is shown in Figs 2 and 3. In the primary analysis, rivaroxaban was non-inferior to enoxaparin (prespecified RR
margin of 1.5) at day 10 in the overall study population
for VTE incidence (2.7% in both arms; RR = 0.97; 95%
CI, 0.71–1.31), and superior to enoxaparin/placebo at

day 35 (4.4% vs. 5.7%, respectively; RR = 0.77; 95% CI,
0.62–0.96; P = 0.02) [14]. In this analysis, rivaroxaban
remained non-inferior to enoxaparin at day 10 in both
D-dimer groups: high D-dimer group, 49/1312 (3.7%)
and 57/1350 (4.2%) patients with VTE for rivaroxaban
and enoxaparin, respectively; low D-dimer group, 20/1517
(1.3%) and 15/1520 (1.0%) patients, respectively. At day 35,
rivaroxaban was superior to enoxaparin/placebo in the
high D-dimer group (VTE incidence rates of 84/1285
[6.5%] vs. 125/1348 [9.3%], respectively), whereas rates
in the low D-dimer group were similar between the
treatment arms (36/1558 [2.3%] vs. 35/1573 [2.2%],
respectively).
In the extended prophylaxis period (days 11–35), rivaroxaban was superior to placebo in the high D-dimer
group (43/1259 [3.4%] vs. 84/1321 [6.4%], respectively).
In contrast, and as seen with the above analyses, patients
in the low D-dimer group had similar incidences of VTE
in both study arms (22/1553 [1.4%] vs. 21/1563 [1.3%],
respectively).
Safety outcomes by D-dimer concentration

Bleeding outcomes by D-dimer group are shown in Fig. 2.
In the overall MAGELLAN study population, major or
non-major clinically relevant bleeding occurred in 2.8% of
patients given rivaroxaban and 1.2% of patients given enoxaparin at day 10 (RR = 2.3; 95% CI, 1.63–3.17;
P < 0.001) [14]. In the high D-dimer group, major or nonmajor clinically relevant bleeding occurred with an incidence of 3.4% (61/1781) in the rivaroxaban arm and 1.7%
(31/1834) in the enoxaparin arm at day 10 (RR = 2.03;
95% CI, 1.32–3.11; P = 0.001), and 2.0% (41/2003) and
0.9% (17/1963), respectively, in the low D-dimer group
(RR = 2.36; 95% CI, 1.35–4.15; P = 0.003).
At day 35, rates of major or non-major clinically relevant bleeding in the overall population were 4.1% among
© 2014 International Society on Thrombosis and Haemostasis
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Table 3 Multivariate logistic regression analysis of VTE up to day 35 (efficacy population)
Likelihood ratio test
Degree(s)
of freedom

Chi square

P value

Comparison for odds ratio

Odds ratio

95% CI

History of DVT/PE
Recent major surgery*
Baseline D-dimer concentration
Active cancer
Creatinine clearance group at
enrolment, mL min 1

1
1
1
1
3

67.42
5.29
39.16
9.34
13.54

< 0.001
0.022
< 0.001
0.002
0.004

Age ≥ 75 years
Baseline hs CRP
Sex
Treatment group
Acute respiratory insufficiency

1
1
1
1
1

8.54
9.86
0.04
4.98
4.71

0.004
0.002
0.83
0.026
0.03

Yes vs. no
Yes vs. no
> 2 9 ULN vs. ≤ 2 9 ULN
Yes vs. no
< 30 vs. > 80
30–< 50 vs. > 80
50–≤ 80 vs. > 80
Yes vs. no
> Median vs. ≤ median†
Female vs. male
Rivaroxaban vs. enoxaparin/placebo
Yes vs. no

5.00
3.08
2.29
1.97
0.52
1.76
1.19
1.53
1.49
1.03
0.76
0.72

3.55–7.05
1.30–7.25
1.75–2.98
1.31–2.97
0.15–1.75
1.22–2.54
0.87–1.64
1.15–2.04
1.16–1.91
0.80–1.31
0.60–0.97
0.54–0.98

Covariate

CI, confidence interval; DVT, deep vein thrombosis; hs–CRP, high-sensitivity C-reactive protein; PE, pulmonary embolism; ULN, upper limit
of normal; VTE, venous thromboembolism. *Within 6–12 weeks. †Includes missing values.

Rivaroxaban

Enoxaparin/placebo
Day 35

Day 10

Rate of venous
thromboembolism, %

10.0
7.5
5.0

P = 0.52
RR = 0.89
95% CI,
0.61–1.29
3.7% 4.2%

2.5
0

P = 0.39
RR = 1.33
95% CI,
0.69–2.60

Rate of major and
nonmajor clinically
relevant bleeding, %

5.0

> 2 × ULN

P = 0.001
RR = 2.03
95% CI,
1.32–3.11
3.4%

2.5

P = 0.87
RR = 1.04
95% CI,
0.66–1.65
2.3% 2.2%

6.5%

≤ 2 × ULN

1.7%

P = 0.003
RR = 2.36
95% CI,
1.35–4.15

> 2 × ULN

P < 0.001
RR = 2.21
95% CI,
1.53–3.20
4.8%

> 2 × ULN

≤ 2 × ULN

P < 0.001
RR = 2.67
95% CI,
1.69–4.20
3.4%

2.2%

2.0%

1.3%

0.9%
0

P < 0.001
RR = 0.54
95% CI,
0.38–0.77
6.4%

3.4%

1.3% 1.0%

10.0
7.5

Days 11–35

P < 0.001
RR = 0.71
95% CI,
0.54–0.92
9.3%

≤ 2 × ULN

> 2 × ULN

≤ 2 × ULN

P = 0.003
RR = 3.09
95% CI,
1.46–6.55

P = 0.004
RR = 3.05
95% CI,
1.44–6.45

1.5%

1.4%
0.5%

> 2 × ULN

≤ 2 × ULN

P = 0.86
RR = 1.05
95% CI,
0.58–1.91
1.4% 1.3%

> 2 × ULN

0.5%
≤ 2 × ULN

Fig. 2. Rates and relative risks of VTE and major plus non-major clinically relevant bleeding at day 10, day 35 and days 11–35. Effect shown
by baseline D-dimer concentration > 2 9 ULN vs. ≤ 2 9 ULN. CI, confidence interval; RR, relative risk; ULN, upper limit of normal;
VTE, venous thromboembolism.

rivaroxaban recipients and 1.7% among enoxaparin/
placebo recipients [14]. For patients in the high D-dimer
group, the equivalent rates at day 35 were 4.8% (86/1781)
and 2.2% (40/1834; RR = 2.21; 95% CI, 1.53–3.20;
P < 0.001). These rates were 3.4% (68/2203) and 1.3%
© 2014 International Society on Thrombosis and Haemostasis

(25/1963), respectively, for the low D-dimer group
(RR = 2.67; 95% CI, 1.69–4.20; P < 0.001). In the day 11–35
analysis, major plus non-major clinically relevant bleeding
occurred at similar rates for rivaroxaban and placebo in
the high and low D-dimer groups: 1.5% (27/1781) vs.
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Rivaroxaban

Enoxaparin/
placebo

RR and 95% CI

Outcome
Baseline D-dimer
concentration

n/N

(%)

n/N

(%)

> 2 × ULN

49/1312

(3.7)

57/1350

(4.2)

≤ 2 × ULN

20/1517

(1.3)

15/1520

(1.0)

> 2 × ULN

84/1285

(6.5)

125/1348

(9.3)

≤ 2 × ULN

36/1558

(2.3)

35/1573

(2.2)

> 2 × ULN

43/1259

(3.4)

84/1321

(6.4)

≤ 2 × ULN

22/1553

(1.4)

21/1563

(1.3)

> 2 × ULN

61/1781

(3.4)

31/1834

(1.7)

≤ 2 × ULN

41/2003

(2.0)

17/1963

(0.9)

> 2 × ULN

86/1781

(4.8)

40/1834

(2.2)

≤ 2 × ULN

68/2003

(3.4)

25/1963

(1.3)

> 2 × ULN

27/1781

(1.5)

9/1834

(0.5)

≤ 2 × ULN

28/2003

(1.4)

9/1963

(0.5)

VTE (day 10)

VTE (day 35)

VTE (days 11–35)

Major and NMCR bleeding
(day 10)

Major and NMCR bleeding
(day 35)

Major and NMCR bleeding
(days 11–35)

0.1

1
Favors
rivaroxaban

10
Favors
enoxaparin/
placebo

Fig. 3. Outcomes and relative risks by time-point for the high and low D-dimer groups. Venous thromboembolism and major plus non-major
clinically relevant bleeding. CI, confidence interval; NMCR, non-major clinically relevant; RR, relative risk; ULN, upper limit of normal.

0.5% (9/1834) in the high D-dimer group (RR = 3.09;
95% CI, 1.46–6.55; P = 0.003) and 1.4% (28/2003) vs.
0.5% (9/1963) in the low D-dimer group (RR = 3.05;
95% CI, 1.44–6.45; P = 0.004).
Overall mortality at day 35 was greater in the high
D-dimer group (5.7% [102/1781] for rivaroxaban vs.
5.7% [104/1834] for enoxaparin/placebo) than the low
D-dimer group (2.2% [45/2003] vs. 2.0% [40/1963]), and
the incidence of all adverse events was also slightly higher
(high D-dimer, 1243/1781 [69.8%] for rivaroxaban vs.
1288/1834 [70.2%] for enoxaparin/placebo; low D-dimer,
1320/2003 [65.9%] vs. 1254/1963 [63.9%], respectively).
Rates for liver function abnormalities up to day 35
varied minimally by D-dimer group and were similar
between the rivaroxaban and enoxaparin/placebo treatment arms; among patients with high baseline D-dimer
concentrations, aspartate aminotransferase was elevated

by > 3 9 ULN vs. baseline in 15/1511 (1.0%) patients in
the rivaroxaban arm and 18/1537 (1.2%) patients in the
enoxaparin/placebo arm; for patients with low baseline
D-dimer concentrations, these rates were 11/1758 (0.6%)
and 17/1758 (1.0%) patients, respectively. Similar results
were found for alanine aminotransferase and bilirubin
concentrations.
Discussion
The MAGELLAN study provides the largest D-dimer
dataset (7581 patients with evaluable concentrations)
accumulated in acutely ill, hospitalized medical patients,
from which the relationship between D-dimer concentration and risk of VTE, and the effect of thromboprophylaxis on this risk, has been evaluated. This analysis shows
that the risk of VTE increases with rising D-dimer
© 2014 International Society on Thrombosis and Haemostasis
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concentration, and patients with a baseline D-dimer concentration > 2 9 ULN are at a 3.5-fold higher risk of
VTE than those with concentrations ≤ 2 9 ULN. Elevated D-dimer concentrations at day 10 were associated
with an increased risk of VTE up to day 35. Multivariate
analysis confirmed that baseline D-dimer concentration is
an independent predictor of VTE risk (OR = 2.29 [95%
CI, 1.75–2.98]) after adjustment for other known risk
factors, and had a similar association to the established
risk factors for VTE of cancer (OR = 1.97 [95% CI,
1.31–2.97]) and age ≥ 75 years (OR = 1.53 [95% CI,
1.15–2.04]).
The area under the ROC curve for D-dimer at baseline
(0.67–0.74) indicated that D-dimer concentration had a
similar predictive value for VTE to validated scores for
assessing the risk of VTE in acutely ill, hospitalized medical patients, namely IMPROVE (0.59–0.65) [11] and
PRETEMED (0.54–0.56) [12,13]. It may be possible to
create a similar score incorporating D-dimer and other
variables to predict the risk of VTE in hospitalized
patients. In particular, high D-dimer levels have been
shown to be predictive of VTE risk and mortality in
patients with cancer [15,16]. However, it was not possible
to postulate such a score using the MAGELLAN data
because the study was insufficiently powered to allow for
a validation cohort in the control arm.
These observations corroborate those of the MEDENOX D-dimer subanalysis in 224 acutely ill, hospitalized
medical patients [8]. In patients who had VTE, median
D-dimer concentrations were significantly higher both at
baseline (day 0; P = 0.01) and at day 10 (P < 0.001)
than in patients without VTE, and all events occurred in
patients who had elevated D-dimer concentrations at
day 0 and day 10 [8]. More recently, a Chinese study in
458 elderly patients also indicated a significant association
between elevated D-dimer concentration and VTE [9];
multivariate analysis showed that patients with raised
baseline D-dimer concentrations had a 3.2-fold increased
risk (95% CI, 1.5–6.5; P = 0.002) of VTE compared with
patients with a normal baseline D-dimer.
In the MAGELLAN primary efficacy analysis, rivaroxaban was non-inferior to enoxaparin at day 10 and
superior to enoxaparin/placebo at day 35 for reductions
in VTE, although the incidence of clinically relevant
bleeding was higher [3]. In this analysis, non-inferiority
was maintained for the high D-dimer group at day 10,
and a more substantial reduction in VTE was achieved
at day 35: rivaroxaban treatment led to reductions of
29% in RR and 2.8% in absolute risk over enoxaparin/
placebo. This benefit was maintained during the
extended prophylaxis period (days 11–35, rivaroxaban
vs. placebo), with reductions in relative and absolute risk
of 46% and 3%, respectively. As in the overall population, incidence rates for major or non-major clinically
relevant bleeding remained higher for rivaroxaban than
for enoxaparin and placebo in both D-dimer groups at
© 2014 International Society on Thrombosis and Haemostasis

all time-points analyzed. These results suggest that
continuing anticoagulant prophylaxis beyond day 10
could be considered in patients with high baseline
D-dimer concentrations but would be unlikely to benefit
those whose baseline D-dimer concentrations were low.
It could be argued that determination of D-dimer concentration at the end of the usual 10-day prophylaxis
period might provide a better indication of whether continued therapy is warranted than pretreatment values.
However, it is likely to be impractical to collect samples
and conduct D-dimer assays at or after hospital discharge and for this reason our study primarily concentrated on baseline D-dimer concentrations, which are
routinely measured on admission.
Our study has limitations. This was a post-hoc analysis
with a retrospectively defined cut-off for D-dimer concentration, and as such our results warrant prospective
confirmation. An objective analysis, such as ultrasound
imaging, was not routinely performed to prove the
absence of thrombosis at the time of baseline D-dimer
testing; however, this is consistent with the usual standard
of care and thus reflects real-life clinical practice. D-dimer
assays have varying sensitivity and specificity, and
because sensitivity and cut-off points vary with the proprietary test, there is no standard for comparing one test
with another. For this reason, a multiple of the ULN was
chosen for the D-dimer cut-off in this study. However, it
should be noted that newer generation tests, such as the
enzyme-linked immunosorbent assay (ELISA) and quantitative latex agglutination methods, are highly sensitive
(> 90%) and are superior to whole-blood D-dimer assays,
latex semi-quantitative assays and latex qualitative assays
[17]. A number of studies have shown that the STA Liatest D-DI assay used in MAGELLAN performs similarly
to the ELISA D-dimer assay [18–20]. Although the use of
a centralized laboratory necessitated the freezing and
transportation of plasma samples, we performed stability
studies that confirmed samples can be stored in this way
for up to 18 months without affecting the results of
D-dimer assays (data on file), a finding that is supported
by an earlier published study [21]. Baseline D-dimer
concentrations were missing in approximately 6.5% of
patients, necessitating imputation of the post-dose value,
but it should be noted that the latter measurements were
taken on the same day as the first dose and would not be
expected to show a relevant difference to the baseline
value. Given that D-dimer assays are widely available
and are used extensively in clinical practice to assist VTE
diagnosis, D-dimer concentration represents a useful marker to aid clinical decision-making.
In summary, an elevated concentration of D-dimer
measured soon after admission is independently associated with the risk of VTE in acutely ill, hospitalized medical patients. Elevated D-dimer was an independent
predictor of VTE, and at least as predictive of VTE as
other more complicated clinical scores. Medical patients

486 A. T. Cohen et al

with high D-dimer levels have been identified not only as
being at particularly high risk of VTE, but also as a
group for whom anticoagulant prophylaxis may provide
an improved benefit–risk profile compared with patients
with low baseline D-dimer. Assessment of D-dimer at the
end of the standard 10-day prophylaxis period may also
provide an indication of risk and benefit from extended
thromboprophylaxis. However, the increased bleeding risk
associated with extended anticoagulation in these patients
necessitates caution, and prospective clinical studies are
required to further investigate these findings.
Addendum
A.T. Cohen (Chair), H.R. Büller, L. Haskell, D. Hu,
R. Hull, A. Mebazaa, G. Merli, S. Schellong, T.E. Spiro,
A.C. Spyropoulos and V.F. Tapson formed the
MAGELLAN Study Steering Committee and each provided substantial input into the design and conduct of the
study, and analysis and interpretation of its results,
including this post-hoc analysis. For this analysis, Y.H.
DeSanctis and M. Homering performed the statistical
analyses of data, and P. Burton contributed substantially
to the design of this analysis and interpretation of the
data. A.T. Cohen and T.E. Spiro were primarily responsible for critically reviewing and revising this manuscript,
but all authors contributed to the revision of the intellectual content and approved the final version of the manuscript to be published.

also undertaken scientific advisory work and speaker
bureau work for Bayer, BMS, Daiichi Sankyo, J&J, Pfizer
and Sanofi. He has undertaken scientific advisory board
work for Portola and speaker bureau work for Boehringer
Ingelheim. T.E. Spiro is a full-time employee of Bayer
HealthCare. A.C. Spyropoulos has received consulting fees
from Astellas, Boehringer Ingelheim, Bristol-Myers Squibb
and J&J. Y.H. DeSanctis has confirmed no conflict of
interest. M. Homering is also an employee of Bayer
HealthCare; H.R. B€
uller has also received fees from Bayer.
L. Haskell is an employee of Janssen Pharmaceuticals. D.
Hu has confirmed that he has no conflict of interest. R.
Hull has undertaken consultancy work for Bayer, Leo
Pharma, Sanofi-Aventis, Pfizer, GSK, Wyeth Pharmaceuticals and Portola Pharmaceuticals. A. Mebazaa has worked
as a Steering Committee consultant for Magellan. G. Merli
has acted as a scientific consultant and received research
support from BMS, J&J and Sanofi-Aventis. S. Schellong
has acted as consultant for, and received speaker fees
from, Bayer, Boehringer, Daiichi, BMS, Sanofi. Dr Schellong has also received speaker fees from GSK and Leo.
V.F. Tapson has received consulting fees from Bayer, Bristol-Myers Squibb, Covidien and Sanofi along with lecture
fees from Covidien and Sanofi. V.F. Tapson has also
received payment for educational presentations from
Sanofi and grant support through his institution from
Bayer and Sanofi. P. Burton is an employee of J&J.
Supporting Information

Acknowledgements

Additional Supporting Information may be found in the
online version of this article:

The authors would like to acknowledge: E. Muehlhofer
and M. Hemmrich, Medical Experts, Bayer HealthCare;
H. Beckmann, R.-I. Schmidt and K. Podwojski, Clinical
Statisticians, Bayer HealthCare; A. Dusczyscyn, Study
Manager, Bayer HealthCare; and K. Mueller, Data Management, Bayer HealthCare. This study was supported by
research funding from Bayer HealthCare Pharmaceuticals
and Janssen Research & Development, LLC (formerly
Johnson & Johnson Pharmaceutical Research & Development, LLC) to the MAGELLAN study group. S. Purver
and S. Atkinson, medical writers supported by funding
from Bayer HealthCare Pharmaceuticals and Janssen
Scientific Affairs, LLC, provided drafts and editorial
assistance to the authors during the preparation of this
manuscript.

Data S1. Appendices.
Fig. S1. Patients included in the analysis and reasons for
exclusion.
Fig. S2. Distribution of D-dimer concentration (lg mL–1)
at baseline versus at Day 10 for patients with and without
venous thromboembolism at Day 35.
Fig. S3. Receiver operating characteristic analysis for
D-dimer at baseline by venous thromboembolism rate at
Day 35.
Table S1. ROC analysis for venous thromboembolism at
Day 10 (per-protocol population) and Day 35 (efficacy
population) by baseline D-dimer group.
Table S2. Area under the receiver operating characteristic
curve for D-dimer at baseline and other VTE risk scores.

Disclosure of Conflicts of Interest

References

A.T. Cohen has undertaken consultancy work and
received honoraria from Astellas, Bayer, Boehringer Ingelheim, BMS, Daiichi Sankyo, GSK, J&J, Mitsubishi
Pharma, Pfizer, Portola, Sanofi and Schering Plough. He
has also received research support from Merck as well as
honoraria and consultancy for Takeda. A.T. Cohen has

1 Cohen AT, Alikhan R, Arcelus JI, Bergmann JF, Haas S, Merli
GJ, Spyropoulos AC, Tapson VF, Turpie AGG. Assessment of
venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients. Thromb Haemost 2005; 94: 750–9.
2 Samama MM, Cohen AT, Darmon JY, Desjardins L, Eldor A,
Janbon C, Leizorovicz A, Nguyen H, Olsson CG, Turpie AG,
Weisslinger N. A comparison of enoxaparin with placebo for the

© 2014 International Society on Thrombosis and Haemostasis

D-dimer correlation with VTE in hospital patients 487

3

4

5

6

7
8

9

10

11

prevention of venous thromboembolism in acutely ill medical
patients. Prophylaxis in Medical Patients with Enoxaparin Study
Group. N Engl J Med 1999; 341: 793–800.
Cohen AT, Spiro TE, B€
uller HR, Haskell L, Hu D, Hull R, Mebazaa A, Merli G, Schellong S, Spyropoulos AC, Tapson V.
MAGELLAN Investigators. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med 2013; 368: 513–23.
Hull RD, Schellong SM, Tapson VF, Monreal M, Samama
MM, Nicol P, Vicaut E, Turpie AG, Yusen RD, for the
EXCLAIM (Extended Prophylaxis for Venous ThromboEmbolism in Acutely Ill Medical Patients With Prolonged Immobilization) study. Extended-duration venous thromboembolism
prophylaxis in acutely ill medical patients with recently reduced
mobility: a randomized trial. Ann Intern Med 2010; 153: 8–18.
Goldhaber SZ, Leizorovicz A, Kakkar AK, Haas SK, Merli G,
Knabb RM, Weitz JI. Apixaban versus enoxaparin for
thromboprophylaxis in medically ill patients. N Engl J Med
2011; 365: 2167–77.
Cohen AT, Spiro TE, B€
uller HR, Haskell L, Hu D, Hull R,
Mebazaa A, Merli G, Schellong S, Spyropoulos A, Tapson V.
Extended-duration rivaroxaban thromboprophylaxis in acutely ill
medical patients: MAGELLAN study protocol. J Thromb
Thrombolysis 2011; 31: 407–16.
Adam SS, Key NS, Greenberg CS. D-dimer antigen: current concepts and future prospects. Blood 2009; 113: 2878–87.
Desjardins L, Bara L, Boutitie F, Samama MM, Cohen AT,
Combe S, Janbon C, Leizorovicz A, Olsson CG, Turpie AG.
Correlation of plasma coagulation parameters with thromboprophylaxis, patient characteristics, and outcome in the MEDENOX
study. Arch Pathol Lab Med 2004; 128: 519–26.
Fan J, Li X, Cheng Y, Yao C, Zhong N. Measurement of Ddimer as aid in risk evaluation of VTE in elderly patients hospitalized for acute illness: a prospective, multicenter study in
China. Clin Invest Med 2011; 34: E96–104.
Courtney DM, Steinberg JM, McCormick JC. Prospective diagnostic accuracy assessment of the HemosIL HS D-dimer to
exclude pulmonary embolism in emergency department patients.
Thromb Res 2010; 125: 79–83.
Spyropoulos AC, Anderson FA Jr, Fitzgerald G, Decousus H,
Pini M, Chong BH, Zotz RB, Bergmann JF, Tapson V, Froehlich JB, Monreal M, Merli GJ, Pavanello R, Turpie AG,
Nakamura M, Piovella F, Kakkar AK, Spencer FA. Predictive
and associative models to identify hospitalized medical patients
at risk for VTE. Chest 2011; 140: 706–14.

© 2014 International Society on Thrombosis and Haemostasis

12 Medrano Ortega FJ, Navarro Puerto A, Vidal Serrano S, Alonso
Ortiz del Rıo C, Gutierrez Tous R, Marın Le
on I. Guıa de
practica clınica basada en la evidencia sobre prevenci
on de enfermedad tromboemb
olica venosa en patologıa medica. 2007.
http://www.a14.san.gva.es/cas/hospital/sesclin/PRETEMED%
20140509.pdf. Accessed 12 September 2013.
13 Gallardo Jimenez P, Guijarro Merino R, Vallejo Herrera V,
Sanchez Morales D, Villalobos Sanchez A, Perell
o GonzalezMoreno JI, G
omez-Huelgas R. Assessment of venous thromboembolism risk in hospitalized medical patients. Concordance
between PRETEMED guide and the recommendations of the
VIII conference of the American College of Chest Physicians.
Med Clin (Barc) 2012; 139: 467–72.
14 Cohen AT, Dobromirski M. The use of rivaroxaban for shortand long-term treatment of venous thromboembolism. Thromb
Haemost 2012; 107: 1035–43.
15 Ay C, Vormittag R, Dunkler D, Simanek R, Chiriac AL, Drach
J, Quehenberger P, Wagner O, Zielinski C, Pabinger I. D-dimer
and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and
Thrombosis Study. J Clin Oncol 2009; 27: 4124–9.
16 Ay C, Dunkler D, Pirker R, Thaler J, Quehenberger P, Wagner
O, Zielinski C, Pabinger I. High D-dimer levels are associated
with poor prognosis in cancer patients. Haematologica 2012; 97:
1158–64.
17 Di Nisio M, Squizzato A, Rutjes AW, B€
uller HR, Zwinderman
AH, Bossuyt PM. Diagnostic accuracy of D-dimer test for exclusion of venous thromboembolism: a systematic review. J Thromb
Haemost 2007; 5: 296–304.
18 Ghanima W, Abdelnoor M, Mowinckel MC, Sandset PM. The
performance of STA-Liatest D-dimer assay in out-patients with
suspected pulmonary embolism. Br J Haematol 2006; 132: 210–5.
19 Lehman CM, Wilson LW, Rodgers GM. Analytic validation and
clinical evaluation of the STA LIATEST immunoturbidimetric
D-dimer assay for the diagnosis of disseminated intravascular
coagulation. Am J Clin Pathol 2004; 122: 178–84.
20 Waser G, Kathriner S, Wuillemin WA. Performance of the automated and rapid STA Liatest D-dimer on the STA-R analyzer.
Thromb Res 2005; 116: 165–70.
21 Woodhams B, Girardot O, Blanco MJ, Colesse G, Gourmelin Y.
Stability of coagulation proteins in frozen plasma. Blood Coagul
Fibrinolysis 2001; 12: 229–36.

